医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Huami Corp to Host Investor Fireside Chat with CEO Wang Huang on July 21

2020年07月09日 AM12:55
このエントリーをはてなブックマークに追加


 

CUPERTINO, Calif. & BEIJING

Huami Corp. and Huami-USA (NYSE: HMI) today announced that it will hold a Fireside Chat conference call for investors on Tuesday, July 21, 2020. The company will discuss its strategy and provide an operational update. Speakers will include Chairman, CEO and founder, Wang Huang; CFO David Cui; and COO Mike Yeung.

The call will begin at 10:00 a.m. EDT U.S. / 10:00 p.m. China Standard Time.

Participants can access the call by dialing +1-888-346-8982, or +1-412-902-4272 for international callers, and ask to be connected to the call for “Huami Corporation”.

A free, live webcast of the conference call will be available on the Investors section of the company’s website at https://www.huami.com/investor. A replay will be archived on the site.

About Huami Corporation (NYSE:HMI)

Huami’s mission is to connect health with technology. Since its inception in 2013, Huami has developed a platform of proprietary technology including AI chips, biometric sensors, and data algorithms, which drive a broadening line of smart health devices for consumers, and analytics services for industry. In 2019, Huami shipped 42.3 million units of smart wearable devices, including its own Amazfit brand, and products developed and manufactured for Xiaomi and Timex, comprising 26% of global category shipments1. Huami Corp is based in Hefei, China, with U.S. operations, Huami-USA, based in Cupertino, Calif.

For more information, please visit https://www.huami.com/investor/pages/company-profile

1 IDC, Correcting and Replacing Shipments of Wearable Devices, 3/10/20

View source version on businesswire.com: https://www.businesswire.com/news/home/20200708005721/en/

CONTACT

For media inquiries:

lydia.huang@huami-usa.com, c: 407-800-5625

For investors:

brad.samson@huami-usa.com, c: 714-955-3951

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表